Key Highlights: Implications: Anupam Rasayan’s acquisition of a 48.2% controlling stake in Bliss GVS Pharma at ₹299/share completes its forward integration into finished‑dose formulations,...
Summary The Top 10 R&D Spending Indian Biopharma Companies of 2026 reflect the country’s growing commitment to pharmaceutical innovation, advanced drug develop...
